Literature DB >> 19542742

Effects of recombinant human relaxin upon proliferation of cardiac fibroblast and synthesis of collagen under high glucose condition.

P Wang1, H W Li, Y P Wang, H Chen, P Zhang.   

Abstract

Cardiac fibrosis is a key component of diabetes and involves the proliferation and differentiation of matrix-producing fibroblasts. We determined the influence of high glucose (HG) conditions on cardiac fibroblasts (CF) functions and the effects of recombinant human (rh) relaxin (RLX) in these responses. We cultured neonatal rat CF in either normal glucose (NG) or HG media. The mRNA of procollagen types I and III, and RLX-1 were assessed by real time PCR and procollagen type I C-terminal peptide (PICP) and procollagen type III amino terminal peptide (PIIINP), matrix metalloproteinases 2 (MMP2), MMP9 were assessed by enzyme linked immunosorbent assay. The results are as follows: a) CF proliferation was significantly increased by HG; rhRLX significantly inhibited HG fibroblast proliferation, while it had no marked effect on CF proliferation in NG. b) CF treated with HG significantly increased the production of PICP and PIIINP. rhRLX had no marked effect on production of PICP and PIIINP in NG. rhRLX blocked the HG-induced increases in collagen synthesis. c) The production of MMP2 and MMP9 is significantly increased by HG. rhRLX decreased overproduction of MMP2 and MMP9 in the presence of HG. d) The RLX- 1 mRNA expression of HG group was higher than in the NG group. We concluded that rhRLX could inhibit both the proliferation of CF and the synthesis of collagen under the HG condition. HG concentration could stimulate the expression of endogenous RLX.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542742     DOI: 10.1007/BF03346460

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  18 in total

1.  Effect of relaxin on myocardial ischemia injury induced by isoproterenol.

Authors:  Jing Zhang; Yong-Fen Qi; Bin Geng; Chun-Shui Pan; Jing Zhao; Li Chen; Jun Yang; Jaw-Kang Chang; Chao-Shu Tang
Journal:  Peptides       Date:  2005-09       Impact factor: 3.750

2.  The pregnancy hormone relaxin is a player in human heart failure.

Authors:  T Dschietzig; C Richter; C Bartsch; M Laule; F P Armbruster; G Baumann; K Stangl
Journal:  FASEB J       Date:  2001-10       Impact factor: 5.191

3.  Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats.

Authors:  Edna D Lekgabe; Helen Kiriazis; Chongxin Zhao; Qi Xu; Xiao Lei Moore; Yidan Su; Ross A D Bathgate; Xiao-Jun Du; Chrishan S Samuel
Journal:  Hypertension       Date:  2005-06-20       Impact factor: 10.190

Review 4.  Monitoring fibrillar collagen turnover in hypertensive heart disease.

Authors:  J Díez; C Laviades
Journal:  Cardiovasc Res       Date:  1997-08       Impact factor: 10.787

5.  Diabetic cardiomyopathy.

Authors:  R I Hamby; S Zoneraich; L Sherman
Journal:  JAMA       Date:  1974-09-23       Impact factor: 56.272

6.  Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus.

Authors:  Ming-Yuh Shiau; Shih-Tzer Tsai; Kan-Jen Tsai; Ming-Lih Haung; Yi-Ting Hsu; Yih-Hsin Chang
Journal:  Mt Sinai J Med       Date:  2006-11

7.  Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent.

Authors:  F Fiordaliso; B Li; R Latini; E H Sonnenblick; P Anversa; A Leri; J Kajstura
Journal:  Lab Invest       Date:  2000-04       Impact factor: 5.662

8.  High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1.

Authors:  R Singh; R H Song; N Alavi; A A Pegoraro; A K Singh; D J Leehey
Journal:  Exp Nephrol       Date:  2001

9.  Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo.

Authors:  Chrishan S Samuel; Elaine N Unemori; Ishanee Mookerjee; Ross A D Bathgate; Sharon L Layfield; John Mak; Geoffrey W Tregear; Xiao-Jun Du
Journal:  Endocrinology       Date:  2004-05-20       Impact factor: 4.736

10.  Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes.

Authors:  Kerrie J Way; Keiji Isshiki; Kiyoshi Suzuma; Tamotsu Yokota; Dmitriy Zvagelsky; Frederick J Schoen; George E Sandusky; Penelope A Pechous; Chris J Vlahos; Hisao Wakasaki; George L King
Journal:  Diabetes       Date:  2002-09       Impact factor: 9.461

View more
  11 in total

1.  The role of thrombospondin-1-mediated TGF-β1 on collagen type III synthesis induced by high glucose.

Authors:  Mengxiong Tang; Fenghua Zhou; Wei Zhang; Zhongxiu Guo; Yuanyuan Shang; Huixia Lu; Ruijuan Lu; Yun Zhang; Yuguo Chen; Ming Zhong
Journal:  Mol Cell Biochem       Date:  2010-09-28       Impact factor: 3.396

2.  Role of protein kinase C β₂ in relaxin-mediated inhibition of cardiac fibrosis.

Authors:  W Su; P Wang; H Chen; H Li
Journal:  J Endocrinol Invest       Date:  2014-04-11       Impact factor: 4.256

Review 3.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 4.  Anti-fibrotic actions of relaxin.

Authors:  C S Samuel; S G Royce; T D Hewitson; K M Denton; T E Cooney; R G Bennett
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

5.  Tempol ameliorates cardiac fibrosis in streptozotocin-induced diabetic rats: role of oxidative stress in diabetic cardiomyopathy.

Authors:  Ashraf Taye; Mekky M Abouzied; Omar M M Mohafez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-08-16       Impact factor: 3.000

6.  Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes.

Authors:  Hooi Hooi Ng; Chen Huei Leo; Darnel Prakoso; Chengxue Qin; Rebecca H Ritchie; Laura J Parry
Journal:  Sci Rep       Date:  2017-01-09       Impact factor: 4.379

7.  Relaxin Level in Patients With Atrial Fibrillation and Association with Heart Failure Occurrence: A STROBE Compliant Article.

Authors:  Hao Zhou; Xiang Qu; Zhan Gao; Gaoshu Zheng; Jie Lin; Lan Su; Zhouqing Huang; Haiying Li; Weijian Huang
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

8.  Relaxin ameliorates high glucose-induced cardiomyocyte hypertrophy and apoptosis via the Notch1 pathway.

Authors:  Xiao Wei; Yuan Yang; Yin-Jiu Jiang; Jian-Ming Lei; Jing-Wen Guo; Hua Xiao
Journal:  Exp Ther Med       Date:  2017-11-06       Impact factor: 2.447

Review 9.  Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Diego Rodríguez-Penas; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera; José R González-Juanatey; Francisca Lago
Journal:  Front Physiol       Date:  2017-08-18       Impact factor: 4.566

Review 10.  Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes.

Authors:  Hooi Hooi Ng; Chen Huei Leo; Laura J Parry; Rebecca H Ritchie
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.